Table 4

Differences in haematological neoplasm-related deaths for patients with SLE and the general Spanish population by lineage

Neoplasm-related deaths n (%)
Non-SLESLEP valueOR (95% CI)*
Haematological12 360 (8.9)18 (19.8)0.0012.546 (1.514 to 4.281)
Malign haematological11 989 (8.6)18 (19.8)0.0012.612 (1.554 to 4.392)
 Lymphoma4237 (3)11 (12.1)<0.0014.208 (2.235 to 7.922)
  Hodgkin’s lymphoma260 (0.2)1 (1)0.1575.752 (0.796 to 41.580)
  Non-Hodgkin’s lymphoma3977 (2.9)10 (11)<0.0014.060 (2.100 to 7.849)
   B cell lineage3537 (2.5)9 (9.9)0.0014.133 (2.071 to 8.246)
   T/NK cell lineage441 (0.3)1 (1)0.2693.064 (0.425 to 22.070)
 Leukaemia4625 (3.3)6 (6.6)0.1291.940 (0.845 to 4.454)
  Myeloid lineage3191 (2.3)4 (4.4)0.2931.916 (0.702 to 5.233)
  Lymphoid lineage1004 (0.7)2 (2.2)0.1402.664 (0.652 to 10.874)
 Multiple myeloma2165 (1.6)00.409
 Myelodisplastic syndrome886 (0.6)01
 Others76 (0.1)1 (1.1)0.049
Unknown behaviour371 (0.3)01
 Myeloproliferative disorders243 (0.2)01
 Others128 (0.1)01
  • Values in bold highlight statistically significant difference.

  • *After adjustment for age, sex, alcohol and tobacco consumption.